Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
Phase of Trial: Phase I/II
Latest Information Update: 20 Apr 2017
Price : $35 *
At a glance
- Drugs REGN 1908-1909 (Primary)
- Indications Hypersensitivity
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 11 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 12 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 12 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.